Peak Pharmaceuticals Won "The Most Brand Value Pharmaceutical Industry Enterprise" Again"


Release time:

2020-01-02

    12Month3Day, the 10th Medical Observer Emerging Forum, the National Medical Elite Club Annual Meeting and2019The annual China Pharmaceutical New Sharp List award ceremony was held in Chongqing, and Peak Pharmaceutical Company won the"2019Annual Most Brand Value Pharmaceutical Industry Enterprise Award ""2019The two awards of the most concerned consistency evaluation variety award of the year.

    The Medical Observer Emerging Forum and the National Medical Elite Club Annual Meeting are the annual ideological feast of the Chinese pharmaceutical industry and have extensive influence in the industry. In this event, 2019Annual China Pharmaceutical New Profits List and2019The annual consistency evaluation list was officially announced. With its rapid development in recent years, Peak Pharmaceuticals has stood out in the selection of brand enterprises and won the"2019The most brand value pharmaceutical industry enterprise of the year ", the product Berunning (olopatadine hydrochloride eye drops) won the"2019The most concerned consistency evaluation variety award of the year ".

   2019The annual China Pharmaceutical Innovation List takes "media viewpoint and new perspective" as its conception and characteristics, focuses on the annual industry phenomenon-level highlights, and makes a list of outstanding enterprises, products and pharmaceutical personnel with prominent capital value in China's pharmaceutical industry during the year, advocating enterprises to enhance their intrinsic value through continuous innovation, thus completing the value transition, thus attracting extensive participation of industry insiders and attention from heavyweight media.

   In this activity, "consistency evaluation varieties" are particularly concerned by the industry. The consistency evaluation of generic drugs makes generic drugs consistent with the original drugs in terms of quality and efficacy, and can replace the original drugs in clinical practice, which can not only save medical expenses, but also improve the quality of generic drugs in China and the overall development level of the pharmaceutical industry, so as to ensure the safe and effective use of drugs by the public. Spike Pharmaceutical 2019Berunning (Olopatadine Hydrochloride Eye Drops), which was introduced in, not only passed the consistency evaluation, but also had the ability to antagonize histamine.H1-The unique effect of receptor and stable mast cell bidirectional anti-allergy is good and fast for the treatment of allergic conjunctivitis in children, and will not cause significant mast cell degranulation, so it is safer to use and has almost no adverse reactions to ocular tissues. It is an ideal drug for the treatment of allergic conjunctivitis at present, winning the unanimous affirmation of experts and peers attending the meeting.